Publications by authors named "Janna-Lisa Velthaus-Rusik"
Article Synopsis
- Circulating tumor cells (CTCs) are critical for understanding tumor diversity and treatment resistance, but traditional methods often capture low numbers, especially in non-small cell lung cancer (NSCLC).
- This study utilized diagnostic leukapheresis (DLA) on six advanced NSCLC patients to access larger blood volumes and employed a new two-step method to enrich CTCs for analysis.
- The results unveiled 3,363 unique CTC transcriptomes, revealing significant heterogeneity and potential distinct phenotypes, which suggests CTCs can serve as valuable indicators for tumor monitoring and targeted therapies in the future.
EGFR exon 20 (EGFR Ex20) insertion mutations in non-small cell lung cancer (NSCLC) are insensitive to traditional EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is the only approved TKI specifically designed to target EGFR Ex20. We performed an international, real-world safety and efficacy analysis on patients with EGFR Ex20-positive NSCLC enrolled in a mobocertinib early access program.
View Article and Find Full Text PDF